Role in the network: The cancer immunotherapy company that absorbed resTORbio 49 days after a federal NIA grant was announced for the nursing home COVID study, inheriting the obligations of a terminated trial whose results were never published — while its CEO (Chen Schor, formerly resTORbio’s CEO) continued running the combined entity and Lloyd Klickstein (ex-NIBR, ex-resTORbio CSO) was appointed to the board in 2024.
Bio
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company trades on NASDAQ under the ticker ACET (formerly TORC when it was resTORbio). It is headquartered in Redwood City, California and Boston, Massachusetts. [1] [2]
Adicet was originally a private company that merged into resTORbio through a reverse merger completed on September 15, 2020. In the merger, Adicet became a wholly-owned subsidiary of resTORbio, which then renamed itself Adicet Bio and changed its mission from anti-aging therapeutics to cancer and autoimmune cell therapy. The merger agreement was signed on April 28, 2020. [3]
As of March 2026, Adicet reported 9,596,407 common shares outstanding following a 1-for-16 reverse stock split in December 2025 — typically a sign of low share price threatening NASDAQ listing requirements. The company’s lead candidate is prula-cel (ADI-001), a gamma delta CAR T cell therapy in Phase 1 trials for lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and rheumatoid arthritis. ADI-270, its solid tumor candidate for kidney cancer, was discontinued in July 2025 for “strategic reprioritization.” [1]
What Adicet Inherited
When the merger completed, Adicet Bio inherited resTORbio’s: [3]
- NASDAQ listing (ticker change TORC → ACET)
- RTB-101 obligations including the NIA-funded nursing home COVID study (NCT04409327)
- Contingent Value Rights (CVR) — contractual obligations to pay resTORbio shareholders if RTB-101 is ever commercialized for COVID
- SEC reporting history under the resTORbio entity
What Adicet did NOT inherit: any interest in aging biology, COVID therapeutics, or the nursing home population. The cancer company had no program, no expertise, and no institutional interest in completing the study it acquired.
What Happened to the Nursing Home Study
The RTB-101 nursing home trial (NCT04409327) was TERMINATED — reason: “Insufficient accrual rate.” The study ran from July 2020 to January 2021, collecting data from enrolled participants before terminating. The results were submitted to a journal and rejected. They were never resubmitted. [4]
Under the ClinicalTrials.gov Final Rule, results for terminated trials must be submitted within 12 months of the primary completion date (December 27, 2020). The record shows the trial’s last update was February 2021, with the study terminated status confirmed in September 2023. Whether results were ever submitted to ClinicalTrials.gov (as distinct from the journal submission) requires further investigation. [4]
~550 elderly nursing home residents participated in a study whose outcomes were never published. The sponsoring company dissolved. The acquiring company had no interest in the research. The data exists somewhere — in Adicet Bio’s files, in the academic researchers’ records (Brown University/Gravenstein), or in the NIA grant files — but it has never been made public.
The People Who Survived
| Person | resTORbio Role | Adicet Bio Role | Status |
|---|---|---|---|
| Chen Schor | CEO | CEO (continuing) | Still CEO as of 2026. Led resTORbio through failure, COVID pivot, merger. Now leads cancer company. |
| Lloyd Klickstein | CSO (previously NIBR) | Board member (appointed Aug 2024) | The NIBR scientist who oversaw RTB-101 now governs the company that buried its results. |
Chen Schor’s career survived the failure of RTB-101, the COVID pivot into nursing homes, the terminated study, and the dissolution of the company he founded. He is now the CEO of a $150M+ market cap biotech developing cutting-edge cell therapies. The nursing home patients’ outcomes were never published. [1] [5]
Current Pipeline (No Aging, No COVID)
| Candidate | Indication | Status |
|---|---|---|
| prula-cel (ADI-001) | Lupus nephritis, SLE, SSc, RA | Phase 1 (multiple FDA Fast Track designations) |
| ADI-270 | Clear cell renal cell carcinoma (kidney cancer) | Discontinued Jul 2025 |
Adicet has zero programs related to aging, COVID, TORC1 inhibition, or elderly populations. The entire resTORbio mission was abandoned. [1]
Timeline
| Date | Event |
|---|---|
| Apr 28, 2020 | Merger agreement signed (resTORbio → Adicet Bio) |
| Sep 15, 2020 | Merger completed. NASDAQ: TORC → ACET. Mission: aging → cancer. |
| 2020-2021 | Nursing home study runs and terminates. Results never published. |
| Aug 2024 | Lloyd Klickstein appointed to Adicet board. NIBR network survives. |
| Jul 2025 | ADI-270 (kidney cancer) discontinued. Pipeline narrows. |
| Dec 2025 | 1-for-16 reverse stock split. Low share price signal. |
| 2026 | Prula-cel Phase 1 continues in autoimmune diseases. Chen Schor still CEO. |
Nodes and Open Questions
- The unpublished data: Where is the nursing home study data? Under the ClinicalTrials.gov Final Rule, terminated studies must report results. Has Adicet Bio fulfilled this obligation? If not, this is a regulatory compliance violation.
- CVR status: Have any commercialization proceeds been triggered for RTB-101 under the CVR? If not, the CVR is worthless — meaning the structure that gave shareholders financial interest in the nursing home study produced zero return while exposing elderly patients to a failed drug.
- Klickstein’s board appointment (August 2024): The former resTORbio CSO was appointed to Adicet’s board four years after the merger. Why bring back a person associated with the terminated nursing home study? Is Klickstein’s board role connected to any revived interest in RTB-101 or aging therapeutics?
- Chen Schor’s continuity: The CEO who oversaw a failed drug trial, a COVID pivot into nursing homes, a terminated study, and a corporate dissolution is still running the resulting company. Has any regulatory body or institutional review board examined his decision-making during the 2020 pivot?
- The reverse stock split: A 1-for-16 split in December 2025 suggests the share price was approaching NASDAQ’s minimum listing threshold (~$1). Adicet’s financial viability as an independent company is uncertain. If Adicet is acquired or dissolved, what happens to the RTB-101 CVR obligations and the nursing home study data?
Sources
[1] [Archive] (https://www.stocktitan.net/sec-filings/ACET/10-k-adicet-bio-inc-files-annual-report-fb581cea0fe0.html)
[2] [Archive] (https://www.businesswire.com/news/home/20250108585728/en/Adicet-Bio-Provides-Corporate-Update-and-Highlights-Expected-2025-Milestones)
[3] [Archive] (https://www.sec.gov/Archives/edgar/data/0001720580/000119312520245865/d50689dex991.htm)
[4] [Archive] (https://clinicaltrials.gov/study/NCT04409327)
[5] Prior investigation sessions — Klickstein NIBR career, resTORbio CSO role